Beam Therapeutics Inc. (BEAM): R&D Expense
$409.62M
Year ended 2025-12-31
$408.66M
Trailing 12 months to 2026-06-30
+9.5%
3-year compound annual growth
+31.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $409.62M | +11.4% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $367.56M | -16.0% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $437.38M | +40.4% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $311.59M | -19.5% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $387.09M | +275.2% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $103.18M | +88.9% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $54.62M | n/a | 2022-02-28, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $409.62M | +11.4% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $37.45M | -75.3% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $243.77M | -42.5% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| ImmunityBio, Inc. (IBRX) | 2024-12-31 | $190.14M | -18.2% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
Compare BEAM, GLUE, ATRA, DNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗